Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 P.M. EDT
Oakville, Ontario--(Newsfile Corp. - June 27, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a...
Staff
Elev8 New Media Named as Winner at PR Daily’s 2022 Top Agencies Awards
LOS ANGELES--(BUSINESS WIRE)--#LosAngeles--Elev8 New Media (“Elev8” or the “Company”), a media and public relations firm specializing in securing media and...
Amai Proteins, producer of 100% protein sweetener that reduces sugar in Food & Beverages by up to 70%, voted Global Winner at the 2022 Extreme Tech Challenge Competition
PALO ALTO, Calif., June 27, 2022 /PRNewswire/ -- Amai Proteins, an Israeli start-up developer of novel designer proteins that answer the...
CoNextions® Inc. Announces Daniel Gruppo as President and Chief Executive Officer
Salt Lake City, Utah, June 27, 2022 (GLOBE NEWSWIRE) -- CoNextions® Inc. Announces Daniel Gruppo as President and Chief Executive...
GUIDEMARK HEALTH AND CYAN HEALTH ARE NOW LUMANITY
GUIDEMARK HEALTH AND CYAN HEALTH ARE NOW LUMANITYName changes come on the heels of being acquired by Lumanity in 2021...
Mountain Valley MD Successfully Completes Pre-Clinical Pharmacokinetic Study For Soluvec™1%
TORONTO, June 27, 2022 (GLOBE NEWSWIRE) -- Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQX: MVMDF)...
Privia Receives HFMA’s MAP Award for High Performance in Revenue Cycle for Seventh Straight Year
ARLINGTON, Va., June 27, 2022 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced that its network of affiliated...
Acer Therapeutics Announces Initiation of its Pivotal Phase 3 DiSCOVER Trial of EDSIVO™ (celiprolol) for the Treatment of Vascular Ehlers-Danlos Syndrome
NEWTON, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a clinical stage pharmaceutical company focused on...
P3 Health Partners Announces Inclusion in the Russell 3000® Index
HENDERSON, Nev., June 27, 2022 (GLOBE NEWSWIRE) -- P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered...
Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain
Presentation delivered by Professor Saoirse O’Sullivan at the 32nd Annual ICRS Symposium in Galway, Ireland on Sunday, June 26thSOLANA BEACH, Calif.,...
WIMI Hologram Academy: The Application of Virtual Reality Technology in Vehicle Driving Training System
HONG KONG, June 27, 2022 (GLOBE NEWSWIRE) -- WIMI Hologram Academy, working in partnership with the Holographic Science Innovation Center,...
SELLAS Life Sciences Provides Clinical Update for GFH009 Ongoing Phase 1 Clinical Trial
- No Dose-Limiting Toxicities Observed in Lymphoma and Acute Myeloid Leukemia Patients at All Dose Levels Studied To-Date - - Early Indications...
Hillstream BioPharma Announces Collaboration with Sapien Biosciences in Cancer Treatments
Investigating the synergy between HSB-1216, a Ferroptosis inducer, and Immune Checkpoint InhibitorsBRIDGEWATER, N.J., June 27, 2022 (GLOBE NEWSWIRE) -- Hillstream...
Mesa Laboratories Appoints Tony Tripeny to its Board of Directors
LAKEWOOD, Colo., June 27, 2022 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) announced the appointment of Tony Tripeny to its...
Noema Pharma Announces FDA Investigational New Drug (IND) Authorization for Orpheus Phase 2b Study of PDE10A Inhibitor Gemlapodect (NOE-105) in Childhood Onset Fluency Disorder
Efficacy and safety study evaluating gemlapodect (NOE-105) in adults with Childhood Onset Fluency Disorder (also known as stuttering)Top-line data expected...
Enzyvant Receives 2022 Rare Impact Industry Innovation Award from the National Organization for Rare Disorders (NORD) for Novel, Tissue-Based Therapy to Treat Ultra-Rare, Life-Threatening Pediatric Condition
Company honored for its work on RETHYMIC® (allogeneic processed thymus tissue-agdc), a one-time, treatment for congenital athymia, an ultra-rare, severe...
High-Quality Botanical Ingredient Producer Linnea SA Celebrates 40 Years of Innovation
RIAZZINO, Switzerland, June 27, 2022 (GLOBE NEWSWIRE) -- Linnea SA (“Linnea” or “the Company”), is proud to announce that it...
C-POLAR™ Technologies, Inc. Launches in the United States
Business Consolidation of C-POLAR™ Biotech Limited Hong Kong and Polarität LLC Complete C-POLARTM Technologies, Inc. launches as an international bioprotection...
Cidara Therapeutics to Host Research and Development Day
Virtual panel discussion will highlight the company’s Cloudbreak® platform and its potential advantages in oncology Event to be held on...
DAXOR ANNOUNCES COOPERATIVE RESEARCH AND DEVELOPMENT PHASE II AGREEMENT WITH THE UNIFORMED ARMED SERVICES UNIVERSITY FOR THE DEVELOPMENT OF A NON-NUCLEAR BLOOD VOLUME ANALYSIS (BVA) DEVICE
New BVA Device Aims to Possess Gold Standard Accuracy and Reproducibility with Increased Safety, Access, Ease of Use, and Frequency...